{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:12:44Z","timestamp":1788876764558,"version":"build-2803163510"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12720-y","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:21:23Z","timestamp":1788870083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging frontiers in adoptive cell therapies: engineering innovations, current challenges, and manufacturing perspectives"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5118-2953","authenticated-orcid":false,"given":"Mahdieh Sadat","family":"Hosseini Nezhad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6063-431X","authenticated-orcid":false,"given":"Sarvenaz","family":"Zeighami Gol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6250-0644","authenticated-orcid":false,"given":"Pouya","family":"Gharavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2248-7708","authenticated-orcid":false,"given":"Hossein","family":"Javid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"5","key":"12720_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s44222-023-00148-z","volume":"2","author":"N Eckman","year":"2024","unstructured":"Eckman N, Nejatfard A, Cavet R, Grosskopf AK, Appel EA (2024) Biomaterials to enhance adoptive cell therapy. Nat Reviews Bioeng 2(5):408\u2013424","journal-title":"Nat Reviews Bioeng"},{"issue":"10","key":"12720_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederst\u00e4dt A, Rezvani K (2022) Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer 22(10):557\u2013575","journal-title":"Nat Rev Cancer"},{"key":"12720_CR3","first-page":"379","volume":"42","author":"Y Chang","year":"2024","unstructured":"Chang Y, Chang M, Bao X, Dong C (2024) Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment. Bioact Mater 42:379\u2013403","journal-title":"Bioact Mater"},{"key":"12720_CR4","doi-asserted-by":"publisher","first-page":"111055","DOI":"10.1016\/j.intimp.2023.111055","volume":"126","author":"F Rastin","year":"2024","unstructured":"Rastin F, Javid H, Oryani MA, Rezagholinejad N, Afshari A-R, Karimi-Shahri M (2024) Immunotherapy for colorectal cancer: rational strategies and novel therapeutic progress. Int Immunopharmacol 126:111055","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"12720_CR5","doi-asserted-by":"publisher","first-page":"20210058","DOI":"10.1002\/EXP.20210058","volume":"3","author":"S Du","year":"2023","unstructured":"Du S, Yan J, Xue Y, Zhong Y, Dong Y (2023) Adoptive cell therapy for cancer treatment. Exploration 3(4):20210058","journal-title":"Exploration"},{"issue":"4","key":"12720_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","volume":"474","author":"MW Rohaan","year":"2019","unstructured":"Rohaan MW, Wilgenhof S, Haanen J (2019) Adoptive cellular therapies: the current landscape. Virchows Arch 474(4):449\u2013461","journal-title":"Virchows Arch"},{"issue":"5","key":"12720_CR7","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","volume":"81","author":"NR Anderson","year":"2021","unstructured":"Anderson NR, Minutolo NG, Gill S, Klichinsky M (2021) Macrophage-Based Approaches for Cancer Immunotherapy. Cancer Res 81(5):1201\u20131208","journal-title":"Cancer Res"},{"issue":"3","key":"12720_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D (2020) NK cells for cancer immunotherapy. Nat Rev Drug Discov 19(3):200\u2013218","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"12720_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12951-025-03448-1","volume":"23","author":"J Luo","year":"2025","unstructured":"Luo J, Cui Y, Xu L, Zhang J, Chen J, Li X et al (2025) Layered double hydroxides for regenerative nanomedicine and tissue engineering: recent advances and future perspectives. J Nanobiotechnol 23(1):370","journal-title":"J Nanobiotechnol"},{"issue":"7","key":"12720_CR10","doi-asserted-by":"publisher","first-page":"e2402250","DOI":"10.1002\/adhm.202402250","volume":"14","author":"Y Han","year":"2025","unstructured":"Han Y, Liu S, Ochieng BO, Gu Y, Kong L, Wang G et al (2025) Multiscale Mechanical Study of Proanthocyanidins for Recovering Residual Stress in Decellularized Blood Vessels. Adv Healthc Mater 14(7):e2402250","journal-title":"Adv Healthc Mater"},{"key":"12720_CR11","doi-asserted-by":"crossref","unstructured":"Neo SY, Xu S, Chong J, Lam KP, Wu J (2023) Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer. J Immunother Cancer 11(4)","DOI":"10.1136\/jitc-2022-006434"},{"key":"12720_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jconrel.2024.02.033","volume":"368","author":"T Zhang","year":"2024","unstructured":"Zhang T, Tai Z, Miao F, Zhang X, Li J, Zhu Q et al (2024) Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances. J Controlled Release 368:372\u2013396","journal-title":"J Controlled Release"},{"key":"12720_CR13","doi-asserted-by":"crossref","unstructured":"Rabbani SA, El-Tanani M, El-Tanani Y, Kumar R, Sharma S, Khan MA et al (2025) Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers. 13(3):190","DOI":"10.3390\/medsci13030190"},{"key":"12720_CR14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jconrel.2019.12.047","volume":"319","author":"TR Abreu","year":"2020","unstructured":"Abreu TR, Fonseca NA, Gon\u00e7alves N, Moreira JN (2020) Current challenges and emerging opportunities of CAR-T cell therapies. J controlled release: official J Controlled Release Soc 319:246\u2013261","journal-title":"J controlled release: official J Controlled Release Soc"},{"issue":"9","key":"12720_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/d41573-022-00095-1","volume":"21","author":"AR Saez-Iba\u00f1ez","year":"2022","unstructured":"Saez-Iba\u00f1ez AR, Upadhaya S, Partridge T, Shah M, Correa D, Campbell J (2022) Landscape of cancer cell therapies: trends and real-world data. Nat Rev Drug Discov 21(9):631\u2013632","journal-title":"Nat Rev Drug Discov"},{"key":"12720_CR16","doi-asserted-by":"publisher","first-page":"1121030","DOI":"10.3389\/fimmu.2023.1121030","volume":"14","author":"M Hiltensperger","year":"2023","unstructured":"Hiltensperger M, Krackhardt AM (2023) Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Front Immunol 14:1121030","journal-title":"Front Immunol"},{"key":"12720_CR17","doi-asserted-by":"crossref","unstructured":"Maia A, Tarannum M, L\u00e9rias JR, Piccinelli S, Borrego LM, Maeurer M et al (2024) Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy. Cells 13(5)","DOI":"10.3390\/cells13050451"},{"key":"12720_CR18","doi-asserted-by":"crossref","unstructured":"Balkhi S, Zuccolotto G, Di Spirito A, Rosato A, Mortara L (2025) CAR-NK cell therapy: promise and challenges in solid tumors. ;Volume 16\u20132025","DOI":"10.3389\/fimmu.2025.1574742"},{"key":"12720_CR19","doi-asserted-by":"publisher","first-page":"1665488","DOI":"10.3389\/fimmu.2025.1665488","volume":"16","author":"J Qian","year":"2025","unstructured":"Qian J, Liu Y (2025) Recent advances in adoptive cell therapy for cancer immunotherapy. Front Immunol 16:1665488","journal-title":"Front Immunol"},{"key":"12720_CR20","doi-asserted-by":"publisher","first-page":"690499","DOI":"10.3389\/fimmu.2021.690499","volume":"12","author":"A Kumar","year":"2021","unstructured":"Kumar A, Watkins R, Vilgelm AE (2021) Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer. Front Immunol 12:690499","journal-title":"Front Immunol"},{"key":"12720_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/cancers14174318","volume":"14","author":"Z Pang","year":"2022","unstructured":"Pang Z, Wang Z, Li F, Feng C, Mu X (2022) Current Progress of CAR-NK Therapy in Cancer Treatment. Cancers (Basel) 14:17","journal-title":"Cancers (Basel)"},{"key":"12720_CR22","doi-asserted-by":"crossref","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY (2024) CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med 221(2)","DOI":"10.1084\/jem.20230903"},{"issue":"2","key":"12720_CR23","first-page":"382","volume":"13","author":"T Lakomy","year":"2023","unstructured":"Lakomy T, Akhoundova D, Nilius H, Kronig M-N, Novak U, Daskalakis M et al (2023) Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or. Treat Outcome 13(2):382","journal-title":"Treat Outcome"},{"key":"12720_CR24","doi-asserted-by":"crossref","unstructured":"Qian J, Liu Y (2025) Recent advances in adoptive cell therapy for cancer immunotherapy Volume 16\u20132025","DOI":"10.3389\/fimmu.2025.1665488"},{"key":"12720_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN (2019) Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev 34:45\u201355","journal-title":"Blood Rev"},{"issue":"1","key":"12720_CR26","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1186\/s12967-024-05703-9","volume":"22","author":"EA Golikova","year":"2024","unstructured":"Golikova EA, Alshevskaya AA, Alrhmoun S, Sivitskaya NA, Sennikov SV (2024) TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges. J translational Med 22(1):897","journal-title":"J translational Med"},{"issue":"4","key":"12720_CR27","first-page":"245","volume":"8","author":"S Liu","year":"2022","unstructured":"Liu S, Nguyen K, Park D, Wong N, Wang A, Zhou Y (2022) Harnessing natural killer cells to develop next-generation cellular immunotherapy. Chronic Dis Transl Med 8(4):245\u2013255","journal-title":"Chronic Dis Transl Med"},{"issue":"1","key":"12720_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen S, Zhu H, Jounaidi Y (2024) Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Ther 9(1):302","journal-title":"Signal Transduct Target Ther"},{"key":"12720_CR29","doi-asserted-by":"publisher","first-page":"1018962","DOI":"10.3389\/fimmu.2022.1018962","volume":"13","author":"MH Kazemi","year":"2022","unstructured":"Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H et al (2022) Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? Front Immunol 13:1018962","journal-title":"Front Immunol"},{"issue":"1","key":"12720_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M et al (2025) CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Therapy 10(1):210","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"12720_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12935-025-03938-0","volume":"25","author":"J Zhu","year":"2025","unstructured":"Zhu J, Zhou J, Tang Y, Huang R, Lu C, Qian K et al (2025) Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions. Cancer Cell Int 25(1):313","journal-title":"Cancer Cell Int"},{"issue":"1","key":"12720_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40814-023-01355-6","volume":"9","author":"M Ahmadvand","year":"2023","unstructured":"Ahmadvand M, Barough MS, Hashemi ZS, Sanati H, Abbasvandi F, Yunesian M et al (2023) Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19. Pilot Feasibility Stud 9(1):137","journal-title":"Pilot Feasibility Stud"},{"issue":"1","key":"12720_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-025-01737-8","volume":"18","author":"N Jiang","year":"2025","unstructured":"Jiang N, Yang Z, Miao H, Xing S, Wang S, Li N (2025) Recent advances in universal chimeric antigen receptor T cell therapy. J Hematol Oncol 18(1):82","journal-title":"J Hematol Oncol"},{"key":"12720_CR34","doi-asserted-by":"crossref","unstructured":"Zhao Y, Deng J, Rao S, Guo S, Shen J, Du F et al (2022) Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges. Cancers 14(17)","DOI":"10.3390\/cancers14174160"},{"key":"12720_CR35","doi-asserted-by":"publisher","first-page":"1601773","DOI":"10.3389\/fimmu.2025.1601773","volume":"16","author":"FP Kraja","year":"2025","unstructured":"Kraja FP, Jurisic VB, Hromi\u0107-Jahjefendi\u0107 A, Rossopoulou N, Katsila T, Mirjacic Martinovic K et al (2025) Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling. Front Immunol 16:1601773","journal-title":"Front Immunol"},{"issue":"1","key":"12720_CR36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12916-021-02006-4","volume":"19","author":"S Wang","year":"2021","unstructured":"Wang S, Sun J, Chen K, Ma P, Lei Q, Xing S et al (2021) Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Med 19(1):140","journal-title":"BMC Med"},{"key":"12720_CR37","doi-asserted-by":"crossref","unstructured":"Ma P, Jiang Y, Zhao G, Wang W, Xing S, Tang Q et al (1990) Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review. European journal of cancer Oxford, England: 2024;209:114224","DOI":"10.1016\/j.ejca.2024.114224"},{"issue":"10","key":"12720_CR38","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","volume":"29","author":"A Betof Warner","year":"2023","unstructured":"Betof Warner A, Corrie PG, Hamid O (2023) Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future. Clin cancer research: official J Am Association Cancer Res 29(10):1835\u20131854","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"12720_CR39","doi-asserted-by":"crossref","unstructured":"Sanomachi T, Katsuya Y, Nakatsura T, Koyama T, Next-Generation CAR-T (2025) and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends. Cancers (Basel) 17(12)","DOI":"10.3390\/cancers17121945"},{"issue":"2","key":"12720_CR40","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/curroncol28020105","volume":"28","author":"S Kang","year":"2021","unstructured":"Kang S, Gao X, Zhang L, Yang E, Li Y, Yu L (2021) The Advances and Challenges of NK Cell-Based Cancer Immunotherapy. Curr Oncol 28(2):1077\u20131093","journal-title":"Curr Oncol"},{"issue":"1","key":"12720_CR41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","volume":"14","author":"Z Lyu","year":"2025","unstructured":"Lyu Z, Niu S, Fang Y, Chen Y, Li YR, Yang L (2025) Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer. Experimental Hematol Oncol 14(1):66","journal-title":"Experimental Hematol Oncol"},{"issue":"1","key":"12720_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10238-025-01559-5","volume":"25","author":"M Rady","year":"2025","unstructured":"Rady M, Mostafa M, Dida G, Sabet F, Abou-Aisha K, Watzl C (2025) Adoptive NK cell therapy in AML: progress and challenges. Clin Exp Med 25(1):41","journal-title":"Clin Exp Med"},{"issue":"22","key":"12720_CR43","first-page":"5657","volume":"14","author":"J Xiao","year":"2022","unstructured":"Xiao J, Zhang T, Gao F, Zhou Z, Shu G, Zou Y et al (2022) Natural Killer Cells: A Promising Kit in the Adoptive. Cell Therapy Toolbox 14(22):5657","journal-title":"Cell Therapy Toolbox"},{"key":"12720_CR44","doi-asserted-by":"publisher","first-page":"1454427","DOI":"10.3389\/fimmu.2024.1454427","volume":"15","author":"H Park","year":"2024","unstructured":"Park H, Kim G, Kim N, Ha S, Yim H (2024) Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis. Front Immunol 15:1454427","journal-title":"Front Immunol"},{"issue":"17","key":"12720_CR45","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.3390\/cancers14174160","volume":"14","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Deng J, Rao S, Guo S, Shen J, Du F et al (2022) Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers 14(17):4160","journal-title":"Cancers"},{"key":"12720_CR46","doi-asserted-by":"publisher","first-page":"1493346","DOI":"10.3389\/fphar.2025.1493346","volume":"16","author":"W He","year":"2025","unstructured":"He W, Cui K, Farooq MA, Huang N, Zhu S, Jiang D et al (2025) TCR-T cell therapy for solid tumors: challenges and emerging solutions. Front Pharmacol 16:1493346","journal-title":"Front Pharmacol"},{"issue":"22","key":"12720_CR47","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.3390\/cancers14225657","volume":"14","author":"J Xiao","year":"2022","unstructured":"Xiao J, Zhang T, Gao F, Zhou Z, Shu G, Zou Y et al (2022) Natural killer cells: a promising kit in the adoptive cell therapy toolbox. Cancers 14(22):5657","journal-title":"Cancers"},{"issue":"5","key":"12720_CR48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/cells13050451","volume":"13","author":"A Maia","year":"2024","unstructured":"Maia A, Tarannum M, L\u00e9rias JR, Piccinelli S, Borrego LM, Maeurer M et al (2024) Building a better defense: expanding and improving natural killer cells for adoptive cell therapy. Cells 13(5):451","journal-title":"Cells"},{"issue":"1","key":"12720_CR49","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00018-025-05727-4","volume":"82","author":"L Hooijmaijers","year":"2025","unstructured":"Hooijmaijers L, Vidal-Manrique M, Spils B, van Ens D, Rodriguez VC, Hobo W et al (2025) Good manufacturing practice production of an off-the-shelf CD34\u2009+\u2009progenitor-derived NK cell product with preserved anti-tumor functionality post-infusion in NOD\/SCID\/IL2Rgnull mice. Cell Mol Life Sci 82(1):210","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"12720_CR50","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen S, Zhu H, Jounaidi Y (2024) Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Therapy 9(1):302","journal-title":"Signal Transduct Target Therapy"},{"issue":"3","key":"12720_CR51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","volume":"43","author":"YR Li","year":"2025","unstructured":"Li YR, Zhou Y, Yu J, Kim YJ, Li M, Lee D et al (2025) Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol 43(3):329\u2013344","journal-title":"Nat Biotechnol"},{"issue":"27","key":"12720_CR52","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1038\/s41388-021-01880-9","volume":"40","author":"X Liu","year":"2021","unstructured":"Liu X, Li L, Si F, Huang L, Zhao Y, Zhang C et al (2021) NK and NKT cells have distinct properties and functions in cancer. Oncogene 40(27):4521\u20134537","journal-title":"Oncogene"},{"issue":"2","key":"12720_CR53","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/biom13020348","volume":"13","author":"T Iyoda","year":"2023","unstructured":"Iyoda T, Yamasaki S, Ueda S, Shimizu K, Fujii S-i (2023) Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer. Biomolecules 13(2):348","journal-title":"Biomolecules"},{"issue":"9","key":"12720_CR54","doi-asserted-by":"publisher","first-page":"102321","DOI":"10.1016\/j.xcrm.2025.102321","volume":"6","author":"YR Li","year":"2025","unstructured":"Li YR, Hu J, Li Z, Zhu E, Chen Y, Halladay T et al (2025) Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell Rep Med 6(9):102321","journal-title":"Cell Rep Med"},{"issue":"10","key":"12720_CR55","doi-asserted-by":"publisher","first-page":"100804","DOI":"10.1016\/j.medj.2025.100804","volume":"6","author":"YR Li","year":"2025","unstructured":"Li YR, Li Z, Zhu Y, Li M, Chen Y, Lee D et al (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med 6(10):100804","journal-title":"Med"},{"issue":"1","key":"12720_CR56","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-025-01736-9","volume":"18","author":"YR Li","year":"2025","unstructured":"Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y et al (2025) Targeting triple-negative breast cancer using cord-blood CD34\u207a HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol 18(1):86","journal-title":"J Hematol Oncol"},{"issue":"1","key":"12720_CR57","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41467-025-56270-6","volume":"16","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Fang Y, Niu S, Zhu Y, Chen Y, Lyu Z et al (2025) Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. Nat Commun 16(1):1248","journal-title":"Nat Commun"},{"key":"12720_CR58","doi-asserted-by":"crossref","unstructured":"Huang J, Yang Q, Wang W, Huang J (2024) CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy. Front Immunol. Volume 15\u20132024","DOI":"10.3389\/fimmu.2024.1378739"},{"issue":"3","key":"12720_CR59","doi-asserted-by":"publisher","first-page":"103957","DOI":"10.1016\/j.xpro.2025.103957","volume":"6","author":"Z Lyu","year":"2025","unstructured":"Lyu Z, Li YR, Yang L (2025) Protocol for assessing pharmacokinetics and pharmacodynamics of human CAR-NKT cells in humanized mouse models using bioluminescence imaging. STAR Protoc 6(3):103957","journal-title":"STAR Protoc"},{"issue":"1","key":"12720_CR60","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-025-01701-6","volume":"18","author":"H Qin","year":"2025","unstructured":"Qin H, Zhou Z, Shi R, Mai Y, Xu Y, Peng F et al (2025) Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects. J Hematol Oncol 18(1):62","journal-title":"J Hematol Oncol"},{"key":"12720_CR61","doi-asserted-by":"crossref","unstructured":"Yang Z, Ha B, Wu Q, Ren F, Yin Z, Zhang HJFI (2025) Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond 16:1544532","DOI":"10.3389\/fimmu.2025.1544532"},{"key":"12720_CR62","doi-asserted-by":"crossref","unstructured":"Ghorashian S, Lucchini G, Richardson R, Nguyen K, Terris C, Guvenel A et al (2024) CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL. 143(2):118\u2013123","DOI":"10.1182\/blood.2023020621"},{"key":"12720_CR63","doi-asserted-by":"crossref","unstructured":"Hou AJ, Chen LC, Chen YYJND (2021) Navigating CAR-T cells through the solid-tumour microenvironment. 20(7):531\u2013550","DOI":"10.1038\/s41573-021-00189-2"},{"key":"12720_CR64","doi-asserted-by":"publisher","first-page":"1399544","DOI":"10.3389\/fonc.2024.1399544","volume":"14","author":"J Luo","year":"2024","unstructured":"Luo J, Zhang X (2024) Challenges and innovations in CAR-T cell therapy: a comprehensive analysis. Front Oncol 14:1399544","journal-title":"Front Oncol"},{"key":"12720_CR65","doi-asserted-by":"publisher","first-page":"1045024","DOI":"10.3389\/fimmu.2023.1045024","volume":"14","author":"K Zhang","year":"2023","unstructured":"Zhang K, Chen H, Li F, Huang S, Chen F, Li Y (2023) Bright future or blind alley? CAR-T cell therapy for solid tumors. Front Immunol 14:1045024","journal-title":"Front Immunol"},{"key":"12720_CR66","doi-asserted-by":"crossref","unstructured":"Duan J, Zhao S, Duan Y, Sun D, Zhang G, Yu D et al (2024) Mnox Nanoenzyme Armed CAR-NK Cells Enhance Solid Tumor Immunotherapy by Alleviating the Immunosuppressive Microenvironment. 13(11):2303963","DOI":"10.1002\/adhm.202303963"},{"key":"12720_CR67","doi-asserted-by":"crossref","unstructured":"Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO et al (2023) Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. 29(2):422\u2013429","DOI":"10.1038\/s41591-022-02182-7"},{"key":"12720_CR68","doi-asserted-by":"crossref","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE et al (2021) A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab. 11(11):2748\u20132763","DOI":"10.1158\/2159-8290.CD-21-0407"},{"key":"12720_CR69","doi-asserted-by":"crossref","unstructured":"Foster MC, Savoldo B, Lau W, Rubinos C, Grover N, Armistead P et al (2021) Utility of a safety switch to abrogate CD19. CAR T-cell\u2013associated neurotoxicity. 137(23):3306\u20133309","DOI":"10.1182\/blood.2021010784"},{"key":"12720_CR70","doi-asserted-by":"crossref","unstructured":"Alsaieedi AA, Zaher KA (2025) Tracing the development of CAR-T cell design: from concept to next-generation platforms Volume 16\u20132025","DOI":"10.3389\/fimmu.2025.1615212"},{"issue":"5","key":"12720_CR71","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C (2025) From concept to cure: The evolution of CAR-T cell therapy. Mol therapy: J Am Soc Gene Therapy 33(5):2123\u20132140","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"issue":"1","key":"12720_CR72","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s43046-025-00262-6","volume":"37","author":"SS Jangavali","year":"2025","unstructured":"Jangavali SS, Hangargekar PB, Gangthade BU, Jadhav SA, Havelikar UA, Joshi AA (2025) From lab to lifesaver: the rise of CAR T-cell therapy in oncology. J Egypt Natl Cancer Inst 37(1):37","journal-title":"J Egypt Natl Cancer Inst"},{"issue":"5","key":"12720_CR73","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.7150\/ijbs.92988","volume":"20","author":"WX Xu","year":"2024","unstructured":"Xu WX, Qu Q, Zhuang HH, Teng XQ, Wei YW, Luo J et al (2024) The Burgeoning Significance of Liquid-Liquid Phase Separation in the Pathogenesis and Therapeutics of Cancers. Int J Biol Sci 20(5):1652\u20131668","journal-title":"Int J Biol Sci"},{"issue":"16","key":"12720_CR74","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1073\/pnas.1817147116","volume":"116","author":"YJ Xie","year":"2019","unstructured":"Xie YJ, Dougan M, Jailkhani N, Ingram J, Fang T, Kummer L et al (2019) Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci USA 116(16):7624\u20137631","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"12720_CR75","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","volume":"28","author":"M Zhang","year":"2022","unstructured":"Zhang M, Chen D, Fu X, Meng H, Nan F, Sun Z et al (2022) Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia\/Lymphoma. Clin Cancer Res 28(13):2830\u20132843","journal-title":"Clin Cancer Res"},{"issue":"1","key":"12720_CR76","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1186\/s12967-024-05461-8","volume":"22","author":"P Safarzadeh Kozani","year":"2024","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F (2024) Humanization of the antigen-recognition domain does not impinge on the antigen-binding, cytokine secretion, and antitumor reactivity of humanized nanobody-based CD19-redirected CAR-T cells. J translational Med 22(1):679","journal-title":"J translational Med"},{"issue":"1","key":"12720_CR77","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1038\/s41467-023-41631-w","volume":"14","author":"D Li","year":"2023","unstructured":"Li D, Wang R, Liang T, Ren H, Park C, Tai C-H et al (2023) Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours. Nat Commun 14(1):5920","journal-title":"Nat Commun"},{"key":"12720_CR78","doi-asserted-by":"crossref","unstructured":"Kasar G, Rasal P, Jagtap M, Surana K, Mahajan S, Sonawane D et al (2025) CAR T-cell structure, manufacturing, applications, and challenges in the management of communityacquired diseases and disorders. Community Acquir Infect 12","DOI":"10.54844\/cai.2024.0780"},{"issue":"1","key":"12720_CR79","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s12967-025-06400-x","volume":"23","author":"D Gupta","year":"2025","unstructured":"Gupta D, Shaz B (2025) Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility. J translational Med 23(1):507","journal-title":"J translational Med"},{"issue":"2","key":"12720_CR80","doi-asserted-by":"publisher","first-page":"200980","DOI":"10.1016\/j.omton.2025.200980","volume":"33","author":"L Abdo","year":"2025","unstructured":"Abdo L, Batista-Silva LR, Bonamino MH (2025) Cost-effective strategies for CAR-T cell therapy manufacturing. Mol therapy Oncol 33(2):200980","journal-title":"Mol therapy Oncol"},{"issue":"23","key":"12720_CR81","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.1182\/bloodadvances.2024012982","volume":"8","author":"\u00c1 Urbano-Ispizua","year":"2024","unstructured":"Urbano-Ispizua \u00c1, Shah NN, Kekre N (2024) Point-of-care CAR T manufacturing solutions: can 1 model fit all? Blood Adv 8(23):6133\u20136136","journal-title":"Blood Adv"},{"issue":"5","key":"12720_CR82","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","volume":"2","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P et al (2021) Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood cancer discovery 2(5):408\u2013422","journal-title":"Blood cancer discovery"},{"issue":"2","key":"12720_CR83","doi-asserted-by":"publisher","first-page":"101250","DOI":"10.1016\/j.omtm.2024.101250","volume":"32","author":"J Dias","year":"2024","unstructured":"Dias J, Garcia J, Agliardi G, Roddie C (2024) CAR-T cell manufacturing landscape-Lessons from the past decade and considerations for early clinical development. Mol therapy Methods Clin Dev 32(2):101250","journal-title":"Mol therapy Methods Clin Dev"},{"key":"12720_CR84","doi-asserted-by":"publisher","first-page":"113392","DOI":"10.1016\/j.intimp.2024.113392","volume":"144","author":"DY Sun","year":"2025","unstructured":"Sun DY, Hu YJ, Li X, Peng J, Dai ZJ, Wang S (2025) Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies. Int Immunopharmacol 144:113392","journal-title":"Int Immunopharmacol"},{"key":"12720_CR85","doi-asserted-by":"publisher","first-page":"1497522","DOI":"10.3389\/fimmu.2024.1497522","volume":"15","author":"M Bida","year":"2024","unstructured":"Bida M, Miya TV, Hull R, Dlamini Z (2024) Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications. Front Immunol 15:1497522","journal-title":"Front Immunol"},{"issue":"2","key":"12720_CR86","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1089\/jir.2022.0172","volume":"43","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wang Q, Yang TW, Yin JM, Wei F, Liu H et al (2023) Analysis of Immune and Inflammatory Microenvironment Characteristics of Noncancer End-Stage Liver Disease. J Interferon Cytokine Res 43(2):86\u201397","journal-title":"J Interferon Cytokine Res"},{"key":"12720_CR87","doi-asserted-by":"publisher","first-page":"114519","DOI":"10.1016\/j.intimp.2025.114519","volume":"155","author":"M Tarin","year":"2025","unstructured":"Tarin M, Oryani MA, Javid H, Karimi-Shahri M, Exosomal (2025) PD-L1 in non-small cell lung Cancer: Implications for immune evasion and resistance to immunotherapy. Int Immunopharmacol 155:114519","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"12720_CR88","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1039\/D3TB02471G","volume":"12","author":"F Rastin","year":"2024","unstructured":"Rastin F, Oryani MA, Iranpour S, Javid H, Hashemzadeh A, Karimi-Shahri M (2024) A new era in cancer treatment: harnessing ZIF-8 nanoparticles for PD-1 inhibitor delivery. J Mater Chem B 12(4):872\u2013894","journal-title":"J Mater Chem B"},{"issue":"3","key":"12720_CR89","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin J, Buettner H, Seedhom MO, Greiner DL, Keck JG, Ishikawa F et al (2023) Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol 20(3):192\u2013206","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"12720_CR90","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.it.2018.07.001","volume":"39","author":"P De La Rochere","year":"2018","unstructured":"De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E (2018) Humanized Mice for the Study of Immuno-Oncology. Trends Immunol 39(9):748\u2013763","journal-title":"Trends Immunol"},{"issue":"1","key":"12720_CR91","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41420-025-02407-x","volume":"11","author":"J Wang","year":"2025","unstructured":"Wang J, Tao X, Zhu J, Dai Z, Du Y, Xie Y et al (2025) Tumor organoid-immune co-culture models: exploring a new perspective of tumor immunity. Cell Death Discov 11(1):195","journal-title":"Cell Death Discov"},{"key":"12720_CR92","doi-asserted-by":"publisher","first-page":"1865487","DOI":"10.3389\/fcell.2026.1865487","volume":"14","author":"L Cai","year":"2026","unstructured":"Cai L, Xiao Y, Xie F, Yang Z (2026) Tumor organoid-immune cell co-culture systems for precision oncology. Front Cell Dev Biol 14:1865487","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"12720_CR93","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","volume":"175","author":"JT Neal","year":"2018","unstructured":"Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J et al (2018) Organoid Modeling of the Tumor Immune Microenvironment. Cell 175(7):1972\u201388e16","journal-title":"Cell"},{"key":"12720_CR94","doi-asserted-by":"crossref","unstructured":"Magr\u00e9 L, Verstegen MMA, Buschow S, van der Laan LJW, Peppelenbosch M, Desai J (2023) Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. J Immunother Cancer 11(5)","DOI":"10.1136\/jitc-2022-006290"},{"issue":"10","key":"12720_CR95","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.21873\/anticanres.14540","volume":"40","author":"YM Morillon","year":"2020","unstructured":"Morillon YM 2nd, Sabzevari A, Schlom J, Greiner JW (2020) The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents. Anticancer Res 40(10):5329\u20135341","journal-title":"Anticancer Res"},{"key":"12720_CR96","doi-asserted-by":"publisher","first-page":"969808","DOI":"10.3389\/fimmu.2022.969808","volume":"13","author":"J He","year":"2022","unstructured":"He J, Shen J, Luo W, Han Z, Xie F, Pang T et al (2022) Research progress on application of single-cell TCR\/BCR sequencing technology to the tumor immune microenvironment, autoimmune diseases, and infectious diseases. Front Immunol 13:969808","journal-title":"Front Immunol"},{"issue":"12","key":"12720_CR97","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1001\/jamaoncol.2025.4072","volume":"11","author":"M Schuiveling","year":"2025","unstructured":"Schuiveling M, van Duin IAJ, Ter Maat LS, van der Weerd JC, Verheijden RJ, van den Berkmortel F et al (2025) Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma. JAMA Oncol 11(12):1470\u20131478","journal-title":"JAMA Oncol"},{"issue":"8","key":"12720_CR98","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.it.2020.06.010","volume":"41","author":"K Yuki","year":"2020","unstructured":"Yuki K, Cheng N, Nakano M, Kuo CJ (2020) Organoid Models of Tumor Immunology. Trends Immunol 41(8):652\u2013664","journal-title":"Trends Immunol"},{"issue":"12","key":"12720_CR99","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/bloodadvances.2024014105","volume":"9","author":"S Gore","year":"2025","unstructured":"Gore S, Blyth E, Bleakley M, Lee K, Micklethwaite K, Gowrishankar K (2025) Current developments in T-cell receptor therapy for acute myeloid leukemia. Blood Adv 9(12):3069\u20133089","journal-title":"Blood Adv"},{"issue":"1","key":"12720_CR100","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41467-024-55420-6","volume":"16","author":"T Kuilman","year":"2025","unstructured":"Kuilman T, Schrikkema DS, Gadiot J, Gomez-Eerland R, Bies L, Walker J et al (2025) Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies. Nat Commun 16(1):649","journal-title":"Nat Commun"},{"issue":"7","key":"12720_CR101","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","volume":"31","author":"M Wermke","year":"2025","unstructured":"Wermke M, Araujo DM, Chatterjee M, Tsimberidou AM, Holderried TAW, Jazaeri AA et al (2025) Autologous T cell therapy for PRAME(+) advanced solid tumors in HLA-A*02(+) patients: a phase 1 trial. Nat Med 31(7):2365\u20132374","journal-title":"Nat Med"},{"issue":"4","key":"12720_CR102","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):69","journal-title":"Blood Cancer J"},{"key":"12720_CR103","doi-asserted-by":"crossref","unstructured":"Bangolo A, Amoozgar B, Mansour C, Zhang L, Gill S, Ip A et al (2025) Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies. Cancers. ;17(2)","DOI":"10.3390\/cancers17020282"},{"issue":"1","key":"12720_CR104","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s44272-025-00044-0","volume":"4","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Han W (2025) Management of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: a comprehensive review. Clin Cancer Bull 4(1):15","journal-title":"Clin Cancer Bull"},{"issue":"1","key":"12720_CR105","doi-asserted-by":"publisher","first-page":"e1009504","DOI":"10.1371\/journal.pcbi.1009504","volume":"18","author":"AB Brummer","year":"2022","unstructured":"Brummer AB, Yang X, Ma E, Gutova M, Brown CE, Rockne RC (2022) Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy. PLoS Comput Biol 18(1):e1009504","journal-title":"PLoS Comput Biol"},{"issue":"4","key":"12720_CR106","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole OO, Bouabdallah K, Mu\u00f1oz J, De Guibert S, Vose JM, Bartlett NL et al (2021) Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol 194(4):690\u2013700","journal-title":"Br J Haematol"},{"key":"12720_CR107","doi-asserted-by":"publisher","first-page":"755639","DOI":"10.3389\/fimmu.2021.755639","volume":"12","author":"M Guercio","year":"2021","unstructured":"Guercio M, Manni S, Boffa I, Caruso S, Di Cecca S, Sinibaldi M et al (2021) Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies. Front Immunol 12:755639","journal-title":"Front Immunol"},{"issue":"12","key":"12720_CR108","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41417-020-00284-3","volume":"28","author":"W Warda","year":"2021","unstructured":"Warda W, Da Rocha MN, Trad R, Haderbache R, Salma Y, Bouquet L et al (2021) Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch. Cancer Gene Ther 28(12):1365\u20131375","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"12720_CR109","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.clml.2024.02.002","volume":"24","author":"Q Shang","year":"2024","unstructured":"Shang Q, Xue L, Lu A, Jia Y, Zuo Y, Zeng H et al (2024) Efficacy and Safety of Children With Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation. Clin Lymphoma Myeloma Leuk 24(6):392\u20139e5","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"12720_CR110","doi-asserted-by":"crossref","unstructured":"Lakomy T, Akhoundova D, Nilius H, Kronig MN, Novak U, Daskalakis M et al (2023) Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome. Biomolecules 13(2)","DOI":"10.3390\/biom13020382"},{"issue":"1","key":"12720_CR111","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","volume":"14","author":"Z Lyu","year":"2025","unstructured":"Lyu Z, Niu S, Fang Y, Chen Y, Li Y-R, Yang L (2025) Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer. Experimental Hematol Oncol 14(1):66","journal-title":"Experimental Hematol Oncol"},{"issue":"10","key":"12720_CR112","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA et al (2023) Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. N Engl J Med 389(10):899\u2013910","journal-title":"N Engl J Med"},{"issue":"20","key":"12720_CR113","doi-asserted-by":"publisher","first-page":"e2427216122","DOI":"10.1073\/pnas.2427216122","volume":"122","author":"NW Engel","year":"2025","unstructured":"Engel NW, Steinfeld I, Ryan D, Anupindi K, Kim S, Wellhausen N et al (2025) Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR\/Cas9 nuclease-engineered T cells. Proc Natl Acad Sci USA 122(20):e2427216122","journal-title":"Proc Natl Acad Sci USA"},{"key":"12720_CR114","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1182\/blood-2023-181869","volume":"142","author":"E Pomeroy","year":"2023","unstructured":"Pomeroy E, Anzalone A, Podracky C, Bloch N, Chang R, Dwivedi A et al (2023) Multiplex Prime Editing and PASSIGE TM for Non-Viral Generation of an Allogeneic CAR-T Cell Product. Blood 142:4803","journal-title":"Blood"},{"issue":"12","key":"12720_CR115","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1016\/j.ymthe.2025.08.032","volume":"33","author":"NS Mikkelsen","year":"2025","unstructured":"Mikkelsen NS, Ravendran S, Broks\u00f8 AD, Skjelbostad SF, Pedersen MG, Fang H et al (2025) Orthogonal CRISPR systems for targeted integration and multiplex base editing enable nonviral engineering of allogeneic CAR-T cells. Mol therapy: J Am Soc Gene Therapy 33(12):6082\u20136100","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"issue":"2","key":"12720_CR116","doi-asserted-by":"publisher","first-page":"102584","DOI":"10.1016\/j.xcrm.2026.102584","volume":"7","author":"J Cheng","year":"2026","unstructured":"Cheng J, Zhu L, Wu J, Zeng Y, Mao X, Ding S et al (2026) Efficacy and safety of autologous CD5-KO anti-CD5 CAR-T cells in relapsed\/refractory CD5(+) hematological malignancies. Cell Rep Med 7(2):102584","journal-title":"Cell Rep Med"},{"key":"12720_CR117","doi-asserted-by":"publisher","first-page":"102010","DOI":"10.1016\/j.eclinm.2023.102010","volume":"60","author":"Y Hu","year":"2023","unstructured":"Hu Y, Zu C, Zhang M, Wei G, Li W, Fu S et al (2023) Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin\u2019s lymphoma: a first-in-human phase I study. EClinicalMedicine 60:102010","journal-title":"EClinicalMedicine"},{"issue":"8075","key":"12720_CR118","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-025-09212-7","volume":"644","author":"AXY Chen","year":"2025","unstructured":"Chen AXY, Yap KM, Kim JS, Sek K, Huang YK, Dunbar PA et al (2025) Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery. Nature 644(8075):241\u2013251","journal-title":"Nature"},{"issue":"8","key":"12720_CR119","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-23-1872","volume":"30","author":"R Nguyen","year":"2024","unstructured":"Nguyen R, Doubrovina E, Mousset CM, Jin BY, Okada R, Zhang X et al (2024) Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy. Clin cancer research: official J Am Association Cancer Res 30(8):1555\u20131566","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"1","key":"12720_CR120","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang G, Wan X (2023) Challenges and new technologies in adoptive cell therapy. J Hematol Oncol 16(1):97","journal-title":"J Hematol Oncol"},{"issue":"4","key":"12720_CR121","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1158\/2643-3230.BCD-23-0272","volume":"5","author":"M Abou-el-Enein","year":"2024","unstructured":"Abou-el-Enein M (2024) The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR\u2009+\u2009T-Cell Malignancy. Blood cancer discovery 5(4):249\u2013257","journal-title":"Blood cancer discovery"},{"issue":"1","key":"12720_CR122","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1186\/s12967-025-07183-x","volume":"23","author":"P Safarzadeh Kozani","year":"2025","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P (2025) Preventing secondary primary malignancies (SPMs) in CAR-T cell therapy through site-specific transgene integration into genomic safe harbors (GSHs). J translational Med 23(1):1155","journal-title":"J translational Med"},{"key":"12720_CR123","doi-asserted-by":"crossref","unstructured":"Shen J, Hu R, Lin A, Jiang A, Tang B, Liu Z et al (2024) Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase. EClinicalMedicine 73","DOI":"10.1016\/j.eclinm.2024.102684"},{"issue":"20","key":"12720_CR124","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix T, Alhomoud M, Shouval R, Cliff ERS, Perales MA, Cordas Dos Santos DM et al (2024) Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients. Clin cancer research: official J Am Association Cancer Res 30(20):4690\u20134700","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"22","key":"12720_CR125","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys PL, Liu CL et al (2024) Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. N Engl J Med 390(22):2047\u20132060","journal-title":"N Engl J Med"},{"issue":"10","key":"12720_CR126","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S (2024) CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol 21(10):1089\u20131108","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"12720_CR127","doi-asserted-by":"publisher","first-page":"26678","DOI":"10.1038\/s41598-024-76791-2","volume":"14","author":"F Jahan","year":"2024","unstructured":"Jahan F, Penna L, Luostarinen A, Veltman L, Hongisto H, L\u00e4hteenm\u00e4ki K et al (2024) Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blasts. Sci Rep 14(1):26678","journal-title":"Sci Rep"},{"issue":"5","key":"12720_CR128","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/mps8050102","volume":"8","author":"S Khanal","year":"2025","unstructured":"Khanal S, Bhattarai N (2025) A Scalable Protocol for Ex Vivo Production of CAR-Engineered Human NK Cells. Methods Protocols 8(5):102","journal-title":"Methods Protocols"},{"issue":"5","key":"12720_CR129","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.stem.2023.02.009","volume":"30","author":"YR Li","year":"2023","unstructured":"Li YR, Dunn ZS, Yu Y, Li M, Wang P, Yang L (2023) Advancing cell-based cancer immunotherapy through stem cell engineering. Cell Stem Cell 30(5):592\u2013610","journal-title":"Cell Stem Cell"},{"issue":"1","key":"12720_CR130","first-page":"27","volume":"52","author":"PL Lindenbergh","year":"2025","unstructured":"Lindenbergh PL, van der Stegen SJC (2025) Adoptive Cell Therapy from the Dish: Potentiating Induced Pluripotent Stem Cells. Transfus Med Hemother 52(1):27\u201341","journal-title":"Transfus Med Hemother"},{"issue":"1","key":"12720_CR131","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12935-024-03479-y","volume":"24","author":"S Mansoori","year":"2024","unstructured":"Mansoori S, Noei A, Maali A, Seyed-Motahari SS, Sharifzadeh Z (2024) Recent updates on allogeneic CAR-T cells in hematological malignancies. Cancer Cell Int 24(1):304","journal-title":"Cancer Cell Int"},{"issue":"1","key":"12720_CR132","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-025-01745-8","volume":"18","author":"J Su","year":"2025","unstructured":"Su J, Zeng Y, Song Z, Liu Y, Ou K, Wu Y et al (2025) Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies. J Hematol Oncol 18(1):90","journal-title":"J Hematol Oncol"},{"issue":"4","key":"12720_CR133","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41551-025-01522-5","volume":"10","author":"F Hu","year":"2026","unstructured":"Hu F, Li J, Wang Y, Lin Y, Zhang J, Xu J et al (2026) Large-scale generation of iNK and CAR-iNK cells from CD34\u2009+\u2009haematopoietic stem and progenitor cells for adoptive immunotherapy. Nat Biomedical Eng 10(4):765\u2013784","journal-title":"Nat Biomedical Eng"},{"key":"12720_CR134","doi-asserted-by":"crossref","unstructured":"Bas\u00edlio-Queir\u00f3s D, Rivi\u00e8re I, van der Stegen SJ, Lachmann N (2025) iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches. Adv Drug Deliv Rev 115713","DOI":"10.1016\/j.addr.2025.115713"},{"issue":"1","key":"12720_CR135","doi-asserted-by":"publisher","first-page":"11666","DOI":"10.1038\/s41467-025-66801-w","volume":"16","author":"T Iinuma","year":"2025","unstructured":"Iinuma T, Kurokawa T, Aoki T, Onodera A, Fukazawa T, Yamada D et al (2025) Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial. Nat Commun 16(1):11666","journal-title":"Nat Commun"},{"key":"12720_CR136","doi-asserted-by":"crossref","unstructured":"Alidadi M, Barzgar H, Zaman M, Paevskaya OA, Metanat Y, Khodabandehloo E et al (2024) Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects. Front Cell Dev Biology Volume 12\u20132024","DOI":"10.3389\/fcell.2024.1491282"},{"issue":"9","key":"12720_CR137","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s41409-025-02637-8","volume":"60","author":"C Marton","year":"2025","unstructured":"Marton C, Cl\u00e9menceau B, Dachy G, Demerle C, Derenne S, Ferrand C et al (2025) Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium. Bone Marrow Transplant 60(9):1209\u20131217","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"12720_CR138","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.bglo.2025.100007","volume":"1","author":"R Sackstein","year":"2025","unstructured":"Sackstein R, Duarte PJ (2025) Latin America and evolving oncotherapeutics using CAR T cells, conjugated antibodies, and bispecific antibodies. Blood Global Hematol 1(2):100007","journal-title":"Blood Global Hematol"},{"issue":"10474","key":"12720_CR139","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0140-6736(24)02719-3","volume":"405","author":"K Senior","year":"2025","unstructured":"Senior K (2025) Making CAR T-cell therapies more affordable. Lancet (London England) 405(10474):187\u2013188","journal-title":"Lancet (London England)"},{"key":"12720_CR140","doi-asserted-by":"publisher","first-page":"896242","DOI":"10.3389\/fimmu.2022.896242","volume":"13","author":"DN Silva","year":"2022","unstructured":"Silva DN, Chrobok M, Rovesti G, Healy K, Wagner AK, Maravelia P et al (2022) Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products. Front Immunol 13:896242","journal-title":"Front Immunol"},{"issue":"8","key":"12720_CR141","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","volume":"21","author":"T Bald","year":"2020","unstructured":"Bald T, Krummel MF, Smyth MJ, Barry KC (2020) The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol 21(8):835\u2013847","journal-title":"Nat Immunol"},{"issue":"3","key":"12720_CR142","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/stcltm\/szad087","volume":"13","author":"A Maia","year":"2024","unstructured":"Maia A, Tarannum M, Romee R (2024) Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy. Stem Cells Transl Med 13(3):230\u2013242","journal-title":"Stem Cells Transl Med"},{"key":"12720_CR143","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez A, Navarro-Zapata A, Escudero A, Matamala N, Ruz-Caracuel B, Mirones I et al (2021) Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy. Cancers (Basel). ;13(3)","DOI":"10.3390\/cancers13030577"},{"key":"12720_CR144","doi-asserted-by":"publisher","first-page":"822298","DOI":"10.3389\/fimmu.2022.822298","volume":"13","author":"KE Ruppel","year":"2022","unstructured":"Ruppel KE, Fricke S, K\u00f6hl U, Schmiedel D (2022) Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy. Front Immunol 13:822298","journal-title":"Front Immunol"},{"issue":"6","key":"12720_CR145","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/1061186X.2025.2467139","volume":"33","author":"F Attarian","year":"2025","unstructured":"Attarian F, Hatamian G, Nosrati S, Akbari Oryani M, Javid H, Hashemzadeh A et al (2025) Role of liposomes in chemoimmunotherapy of breast cancer. J Drug Target 33(6):887\u2013915","journal-title":"J Drug Target"},{"key":"12720_CR146","doi-asserted-by":"publisher","first-page":"101073","DOI":"10.1016\/j.blre.2023.101073","volume":"60","author":"A Merino","year":"2023","unstructured":"Merino A, Maakaron J, Bachanova V (2023) Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting. Blood Rev 60:101073","journal-title":"Blood Rev"},{"key":"12720_CR147","doi-asserted-by":"publisher","first-page":"1603792","DOI":"10.3389\/fimmu.2025.1603792","volume":"16","author":"S Liu","year":"2025","unstructured":"Liu S, Jiang W, Sheng J, Wang L, Cui M (2025) Adoptive cell therapy for cancer: combination strategies and biomarkers. Front Immunol 16:1603792","journal-title":"Front Immunol"},{"key":"12720_CR148","doi-asserted-by":"publisher","first-page":"rbaf007","DOI":"10.1093\/rb\/rbaf007","volume":"12","author":"X Liu","year":"2025","unstructured":"Liu X, Yu L, Xiao A, Sun W, Wang H, Wang X et al (2025) Analytical methods in studying cell force sensing: principles, current technologies and perspectives. Regen Biomater 12:rbaf007","journal-title":"Regen Biomater"},{"issue":"1","key":"12720_CR149","doi-asserted-by":"publisher","first-page":"102537","DOI":"10.1016\/j.xcrm.2025.102537","volume":"7","author":"A Li","year":"2026","unstructured":"Li A, Xu S, Fan J, Liu J, Song X, Cao L et al (2026) 5-HT reuptake blockade induces pyroptosis in BRAF(V600E)-mutated melanomas via remodeling histone serotonylation. Cell Rep Med 7(1):102537","journal-title":"Cell Rep Med"},{"key":"12720_CR150","doi-asserted-by":"publisher","first-page":"1490911","DOI":"10.3389\/fimmu.2024.1490911","volume":"15","author":"O Nolan-Stevaux","year":"2024","unstructured":"Nolan-Stevaux O, Smith R (2024) Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies. Front Immunol 15:1490911","journal-title":"Front Immunol"},{"issue":"1","key":"12720_CR151","doi-asserted-by":"publisher","first-page":"2055703","DOI":"10.1080\/2162402X.2022.2055703","volume":"11","author":"Q Yang","year":"2022","unstructured":"Yang Q, Hao J, Chi M, Wang Y, Xin B, Huang J et al (2022) Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism. Oncoimmunology 11(1):2055703","journal-title":"Oncoimmunology"},{"issue":"640","key":"12720_CR152","doi-asserted-by":"publisher","first-page":"eabn2231","DOI":"10.1126\/scitranslmed.abn2231","volume":"14","author":"L Evgin","year":"2022","unstructured":"Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J et al (2022) Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med 14(640):eabn2231","journal-title":"Sci Transl Med"},{"issue":"17","key":"12720_CR153","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","volume":"384","author":"GK Friedman","year":"2021","unstructured":"Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I et al (2021) Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. N Engl J Med 384(17):1613\u20131622","journal-title":"N Engl J Med"},{"issue":"6","key":"12720_CR154","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.ymthe.2024.04.004","volume":"32","author":"T Ahn","year":"2024","unstructured":"Ahn T, Bae EA, Seo H (2024) Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors. Mol therapy: J Am Soc Gene Therapy 32(6):1617\u20131627","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"issue":"14","key":"12720_CR155","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1182\/blood.2021015016","volume":"139","author":"JV Tandel","year":"2022","unstructured":"Tandel JV, Gill SI (2022) Epigenetic engineering empowers T cells. Blood 139(14):2091\u20132092","journal-title":"Blood"},{"key":"12720_CR156","doi-asserted-by":"publisher","first-page":"100053","DOI":"10.1016\/j.bict.2026.100053","volume":"2","author":"N Shah","year":"2026","unstructured":"Shah N, Urbano-Ispizua A, Annunzio K, L\u00f3pez L, Olesti E, Bassett E et al (2026) Decentralized CAR-T Manufacturing: Highlighting Regulatory Pathways in the United States and Abroad. Blood Immunol Cell Therapy 2:100053","journal-title":"Blood Immunol Cell Therapy"},{"key":"12720_CR157","doi-asserted-by":"crossref","unstructured":"Cl\u00e9 DV, Donadel CD, Calado RT (2025) CAR-T in resource-limited regions. Blood Global Hematol. ;2(1)","DOI":"10.1016\/j.bglo.2025.100051"},{"issue":"1","key":"12720_CR158","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-023-01435-3","volume":"16","author":"R Huang","year":"2023","unstructured":"Huang R, Wen Q, Zhang X (2023) CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022. J Hematol Oncol 16(1):35","journal-title":"J Hematol Oncol"},{"issue":"1","key":"12720_CR159","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","volume":"15","author":"N Lamers-Kok","year":"2022","unstructured":"Lamers-Kok N, Panella D, Georgoudaki AM, Liu H, \u00d6zkazanc D, Ku\u010derov\u00e1 L et al (2022) Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. J Hematol Oncol 15(1):164","journal-title":"J Hematol Oncol"},{"key":"12720_CR160","doi-asserted-by":"crossref","unstructured":"Li W, Wang X, Zhang X, Aziz AUR, Wang D (2024) CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges. Biomolecules 14(8)","DOI":"10.3390\/biom14081035"},{"issue":"2","key":"12720_CR161","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bjh.17186","volume":"193","author":"H Rafei","year":"2021","unstructured":"Rafei H, Daher M, Rezvani K (2021) Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol 193(2):216\u2013230","journal-title":"Br J Haematol"},{"issue":"7","key":"12720_CR162","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.ymthe.2024.05.022","volume":"32","author":"T Bexte","year":"2024","unstructured":"Bexte T, Botezatu L, Miskey C, Gierschek F, Moter A, Wendel P et al (2024) Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors. Mol Ther 32(7):2357\u20132372","journal-title":"Mol Ther"},{"issue":"1","key":"12720_CR163","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-023-00482-9","volume":"11","author":"M Mazinani","year":"2023","unstructured":"Mazinani M, Rahbarizadeh F (2023) New cell sources for CAR-based immunotherapy. Biomark Res 11(1):49","journal-title":"Biomark Res"},{"key":"12720_CR164","doi-asserted-by":"crossref","unstructured":"Moradi V, Omidkhoda A, Ahmadbeigi N (2023) The paths and challenges of off-the-shelf CAR-T cell therapy: An overview of clinical trials, vol 169. Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie, p 115888","DOI":"10.1016\/j.biopha.2023.115888"},{"issue":"20","key":"12720_CR165","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"M Elsallab","year":"2024","unstructured":"Elsallab M, Ellithi M, Lunning MA, D\u2019Angelo C, Ma J, Perales MA et al (2024) Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood 143(20):2099\u20132105","journal-title":"Blood"},{"key":"12720_CR166","doi-asserted-by":"publisher","first-page":"102684","DOI":"10.1016\/j.eclinm.2024.102684","volume":"73","author":"J Shen","year":"2024","unstructured":"Shen J, Hu R, Lin A, Jiang A, Tang B, Liu Z et al (2024) Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase. EClinicalMedicine 73:102684","journal-title":"EClinicalMedicine"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12720-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:03:39Z","timestamp":1788876219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12720-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":166,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12720"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12720-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"5 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval is not applicable for this type of article (review).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1554"}}